Palexia - Key
Palexia - Key Visual

PALEXIA® IR:
Immediate Release for
acute pain sensations21,22

Palexia® immediate release (IR) formulation is available in film-coated tablets or in an oral solution and is intended for acute pain situations.21,22

Palexia - Key Visual - Efficacy

Indication and usage

Palexia® IR is indicated for the relief of moderate to severe acute pain in adults, which can be adequately managed only with opioid analgesics.21,22

PALEXIA® IR: FOR MODERATE TO SEVERE ACUTE PAIN.21,22


Palexia - Key Visual - Tolerability

Formulation

Palexia® immediate release (IR) formulation is available in film-coated tablets or in an oral solution

Palexia® immediate release (IR) film-coated tablets are available in different dosages:21,22

Palexia® IR 50 mg film-coated tablets
Palexia® IR 75 mg film-coated tablets
Palexia® IR 100 mg film-coated tablets

Palexia® immediate release (IR) oral Solution is available in two different concentrations:21,22

Palexia® IR 4 mg/ml oral solution
Palexia® IR 20 mg/ml oral solution

PALEXIA® IR: AVAILABLE IN DIFFERENT STRENGTHS AND FORMULATIONS*21,22


Palexia - Key Visual - Stay on therapy

Posology and method of administration

The dosing regimen should be individualised according to the severity of pain being treated, the previous treatment experience and the ability to monitor the patient.21,22

Patients should start treatment with single doses of 50 mg tapentadol as film-coated tablet21 or as an oral solution22 administered every 4 to 6 hours. Higher starting doses may be necessary depending on the pain intensity and the patient’s previous history of analgesic requirements.21,22

On the first day of dosing, an additional dose may be taken as soon as one hour after the initial dose, if pain control is not achieved. The dose should then be titrated individually to a level that provides adequate analgesia and minimises undesirable effects under the close supervision of the prescribing physician.21,22

Daily doses greater than 700 mg tapentadol on the first day of treatment and maintenance daily doses greater than 600 mg tapentadol have not been studied and are therefore not recommended.21,22

PALEXIA® IR: RELIEVES PAIN AFTER 30 MINUTES FOR UP TO 6 HOURS!21,22


Palexia - Key Visual - Efficacy

Duration of treatment

The film-coated tablets21 and oral solutions22 are intended for acute pain situations. If longer-term treatment is anticipated or becomes necessary and effective pain relief in the absence of intolerable adverse events was achieved with Palexia® IR, the possibility of switching the patient to therapy with Palexia® PR prolonged release tablets should be considered. As with all symptomatic treatments, the continued use of tapentadol must be evaluated on an ongoing basis.21,22

For further information, including contraindications please refer to the full Summary of Product Characteristics.21,22

PALEXIA® IR: PROVIDING THE SAME PALEXIA® BENEFITS TO YOUR PATIENTS!21,22


View footnotes

*Not all the formulations and strengths are available in every country.